The School Board That Had to Choose Between Teachers and Ozempic

A school board should never have to choose between classroom funding and pharmacy costs. But that is exactly where many districts are headed. Across the country, public-sector employers are discovering that GLP-1 drug spending is no longer a future problem — it is already showing up in renewals, reserve projections, and budget discussions. And unlike private corporations, school districts cannot simply absorb these increases quietly.

Most districts function within fixed budgets that are approved well in advance. Revenue growth is often limited. Labor costs are largely predetermined. Benefit costs compete directly against educational priorities. That means healthcare inflation is not simply a financial issue. It becomes an educational issue. Every additional dollar spent on healthcare is a dollar unavailable for teacher salaries, classroom technology, student programs, and educational resources.

Why This Is Not Really a Pharmacy Problem

Most organizations initially approach GLP-1 utilization as a pharmacy problem. Those tools may temporarily reduce spending. But they do not address the underlying issue. The underlying issue is metabolic health. A workforce that is becoming progressively less healthy will continue generating higher claims costs regardless of how a particular medication is covered.

School boards should not be forced to choose between classrooms and healthcare. The goal should be creating strategies that improve employee health while reducing long-term cost pressure. Because the real issue is not Ozempic. The real issue is the health trajectory of the workforce.